Acutaas Chemicals FY26 Results: Revenue up 33% to ₹13,394 Mn, PAT more than doubles
- Consolidated revenue from operations rose 33% YoY to ₹13,394 Mn in FY2026, with PAT surging 122% to ₹3,564 Mn
- EBITDA more than doubled to ₹4,804 Mn; EBITDA margin expanded to 35.90% from 23.00% in FY2025
- Advanced Pharmaceutical Intermediates segment grew 37.5% YoY to ₹11,741 Mn, driven by CDMO business
- Phase 1 battery chemicals plant inaugurated at Jhagadia with 2,000 MTPA capacity each for VC and FEC; fully covered by long-term contracts
- RoCE reached a record 39.30% in FY2026; final dividend of ₹2.50 per share recommended for FY2026

*this image is generated using AI for illustrative purposes only.
Acutaas Chemicals Limited (formerly Ami Organics Limited) delivered a landmark FY2026, with consolidated revenue from operations rising 33% year-on-year to ₹13,394 Mn and profit after tax surging 122% to ₹3,564 Mn.
The Gujarat-headquartered specialty chemicals company filed its Annual Report for FY2025-26 on August 29, 2026, ahead of its 19th Annual General Meeting scheduled for September 24, 2026. The results reflect broad-based growth across its pharmaceutical intermediates and emerging specialty chemicals verticals, with EBITDA more than doubling to ₹4,804 Mn and EBITDA margin expanding sharply to 35.9% from 23.0% in FY2025.
Key Financial Highlights
The following table summarises consolidated financial performance across the last three fiscal years.
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue from Operations (₹ Mn) | 13,394 | 10,069 | 7,175 |
| Operating EBITDA (₹ Mn) | 4,804 | 2,321 | 1,285 |
| Operating EBITDA Margin (%) | 35.90 | 23.00 | 17.90 |
| Profit Before Tax (₹ Mn) | 4,827 | 2,162 | 819 |
| Profit After Tax (₹ Mn) | 3,564 | 1,604 | 808* |
| PAT Margin (%) | 26.60 | 15.90 | 11.30 |
| Revenue from Exports (₹ Mn) | 10,213 | 7,426 | 3,997 |
| Return on Equity (%) | 32.50 | 15.10 | 11.40 |
| Return on Capital Employed (%) | 39.30 | 19.10 | 12.60 |
*Adjusted for exceptional items. RoE and RoCE adjusted for cash and cash equivalents, exceptional items, and CWIP.
The Advanced Pharmaceutical Intermediates segment, the company's largest, grew 37.5% year-on-year to ₹11,741 Mn, driven primarily by the CDMO business. The Specialty Chemicals segment registered growth of 8.0%, achieving revenue of ₹1,652 Mn. Exports contributed approximately 77% of total revenue in FY2026.
Business Segment Performance
Pharmaceutical Intermediates and CDMO
The pharmaceutical intermediates business, which commands 50–90% global market share in key molecules, served 160+ customers across 25+ countries and 17+ therapeutic areas from two manufacturing facilities. During FY2026, four additional CDMO products were successfully validated, adding to the company's anchor innovator contract. The Ankleshwar manufacturing facility received Good Manufacturing Practices (GMP) certification from the Pharmaceutical and Medical Devices Agency, Japan (PMDA), without any critical or major observations.
Battery Chemicals
Phase 1 of the battery chemicals project at Jhagadia, Gujarat, was inaugurated on January 19, 2026, establishing annual production capacity of 2,000 MTPA each for Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC). Acutaas is India's first electrolyte additives manufacturer. The entire commercialised capacity is covered by long-term customer contracts for the next three years. FY2027 is expected to be the first year of revenue contribution from this segment.
Semiconductor Chemicals
The semiconductor chemicals business, anchored by Baba Fine Chemicals — India's only manufacturer of photoresist chemicals — generated ₹157 Mn in revenue. During FY2026, approximately ₹2,000 Mn was invested in Indichem Inc., a joint venture with South Korea's J & Materials Co. Ltd., to establish an advanced semiconductor chemicals facility in Gongju, South Korea. The R&D centre at this facility is already operational and supplying samples to prospective customers. The manufacturing facility is under construction and expected to be on stream in H2 CY26.
Capital Allocation and Balance Sheet
Capex deployed in FY2026 stood at ₹1,950 Mn, directed primarily towards the Jhagadia battery chemicals project, a new pilot plant, and routine maintenance. The company's multi-year capex programme spanning FY2023 to FY2030 totals ₹10,000+ Mn across five pillars.
| Capex Pillar | Investment | Status |
|---|---|---|
| Pharma | ₹3,200 Mn | Completed |
| Battery Chemicals | ₹2,200 Mn | Partially completed |
| Semiconductor | ₹2,000 Mn | Under construction |
| R&D | ₹250 Mn | Under construction |
| Solar Power | ₹500 Mn | Completed |
| Electronic Grade Chemicals | ₹2,120 Mn | Announced |
Net cash and cash equivalents stood at ₹1,983 Mn as on March 31, 2026. The debt-equity ratio was 0.02x. Working capital days moved from 114 days to 120 days. RoCE reached a company record of 39.3% in FY2026, up from 19.1% in FY2025.
Dividend and Corporate Actions
The Board of Directors recommended a final dividend of ₹2.50 per equity share of face value ₹5 each (50% of face value) for FY2025-26, subject to shareholder approval at the 19th AGM. The total dividend outgo, if declared, would amount to ₹204.68 Mn. The record date for dividend eligibility is September 17, 2026.
During the year, the company completed its rebranding from Ami Organics Limited to Acutaas Chemicals Limited, effective May 15, 2025. Subsidiary names were also aligned: Baba Advance Materials Limited was renamed Acutaas Advance Material Limited, and Ami Organics Electrolytes Private Limited was renamed Acutaas Chemicals Electrolytes Private Limited.
ESG and Operational Highlights
Acutaas received the EcoVadis Platinum rating in August 2025, placing it in the top 1% of companies assessed globally. The company also received the Responsible Care certification from the Indian Chemical Council and was recognised as a Great Place To Work. Renewable energy capacity installed stands at 16 MW, with solar power meeting 52% of electricity requirements at the Ankleshwar and Jhagadia facilities. Total waste recycled reached 85% through GPCB-approved recyclers, with zero safety-related incidents and zero regulatory incidents reported for FY2026.
The R&D team comprises 130+ professionals including 30+ PhDs, supported by a DSIR-approved centre spanning 2,200 sq. mt. The company holds 29 process patents (10 granted, 9 published, 10 under publication).
Historical Stock Returns for Acutaas Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.43% | +2.21% | -2.56% | +52.01% | +132.14% | 0.0% |
How will the transition to revenue generation from the Jhagadia battery chemicals facility in FY2027 impact Acutaas's overall margin profile given the competitive landscape of electrolyte additives?
What are the strategic implications of the ₹2,000 Mn investment in Indichem Inc. for Acutaas's foothold in the high-barrier semiconductor chemicals market, particularly regarding customer adoption timelines?
With exports constituting 77% of revenue, how exposed is Acutaas to potential geopolitical trade barriers or currency fluctuations, and what mitigation strategies are in place for its key markets?

































